IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,686,639 | +8.5% | 35,389 | -1.3% | 0.01% | +9.1% |
Q1 2024 | $1,554,098 | -7.3% | 35,850 | +8.1% | 0.01% | -15.4% |
Q4 2023 | $1,677,109 | -8.7% | 33,151 | -18.1% | 0.01% | -18.8% |
Q3 2023 | $1,835,946 | -13.8% | 40,475 | -22.1% | 0.02% | -5.9% |
Q2 2023 | $2,130,524 | -6.2% | 51,926 | -18.3% | 0.02% | -10.5% |
Q1 2023 | $2,271,741 | -3.2% | 63,563 | +2.3% | 0.02% | -9.5% |
Q4 2022 | $2,347,745 | -3.4% | 62,159 | +13.1% | 0.02% | -4.5% |
Q3 2022 | $2,431,000 | +3.0% | 54,969 | -13.8% | 0.02% | +15.8% |
Q2 2022 | $2,360,000 | -6.6% | 63,746 | -6.6% | 0.02% | +26.7% |
Q1 2022 | $2,528,000 | +13.8% | 68,237 | -6.5% | 0.02% | +25.0% |
Q4 2021 | $2,221,000 | +5.7% | 72,978 | +16.5% | 0.01% | -7.7% |
Q3 2021 | $2,101,000 | -6.2% | 62,637 | +11.6% | 0.01% | 0.0% |
Q2 2021 | $2,239,000 | -30.2% | 56,136 | -21.4% | 0.01% | -38.1% |
Q1 2021 | $3,210,000 | -6.7% | 71,392 | +17.3% | 0.02% | -4.5% |
Q4 2020 | $3,441,000 | -2.3% | 60,854 | -18.0% | 0.02% | -12.0% |
Q3 2020 | $3,522,000 | -24.2% | 74,221 | -5.9% | 0.02% | -30.6% |
Q2 2020 | $4,648,000 | +49.2% | 78,836 | +19.6% | 0.04% | +16.1% |
Q1 2020 | $3,115,000 | -35.8% | 65,890 | -18.0% | 0.03% | -13.9% |
Q4 2019 | $4,855,000 | +20.4% | 80,367 | +19.3% | 0.04% | +12.5% |
Q3 2019 | $4,034,000 | -11.4% | 67,342 | -4.9% | 0.03% | -13.5% |
Q2 2019 | $4,551,000 | -22.9% | 70,809 | -2.7% | 0.04% | -22.9% |
Q1 2019 | $5,905,000 | +30.3% | 72,746 | -13.2% | 0.05% | +26.3% |
Q4 2018 | $4,532,000 | -8.8% | 83,838 | -13.0% | 0.04% | +18.8% |
Q3 2018 | $4,968,000 | +24.5% | 96,317 | +0.6% | 0.03% | +18.5% |
Q2 2018 | $3,991,000 | -0.8% | 95,767 | +4.9% | 0.03% | +170.0% |
Q1 2018 | $4,024,000 | -10.5% | 91,282 | +2.1% | 0.01% | -9.1% |
Q4 2017 | $4,497,000 | -13.7% | 89,389 | -13.0% | 0.01% | -8.3% |
Q3 2017 | $5,209,000 | +4.0% | 102,755 | +4.4% | 0.01% | -7.7% |
Q2 2017 | $5,007,000 | +6.3% | 98,439 | -16.0% | 0.01% | 0.0% |
Q1 2017 | $4,709,000 | +2.8% | 117,155 | +22.4% | 0.01% | 0.0% |
Q4 2016 | $4,579,000 | -9.8% | 95,729 | -30.9% | 0.01% | -18.8% |
Q3 2016 | $5,078,000 | +48.3% | 138,566 | -5.8% | 0.02% | +45.5% |
Q2 2016 | $3,424,000 | -33.3% | 147,037 | +16.1% | 0.01% | -31.2% |
Q1 2016 | $5,130,000 | -46.8% | 126,678 | -18.6% | 0.02% | -42.9% |
Q4 2015 | $9,639,000 | – | 155,640 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |